Holen Sie sich die Stockscreener-App
4.71
1.67%
-0.08
Handel nachbörslich:
4.75
0.04
+0.85%
Schlusskurs vom Vortag:
$4.79
Offen:
$4.68
24-Stunden-Volumen:
28,494
Relative Volume:
0.04
Marktkapitalisierung:
$6.78M
Einnahmen:
$3.50M
Nettoeinkommen (Verlust:
$-37.33M
KGV:
-4.71
EPS:
-1
Netto-Cashflow:
$-19.15M
1W Leistung:
+6.56%
1M Leistung:
-11.13%
6M Leistung:
-68.18%
1J Leistung:
-82.01%
1-Tages-Spanne:
$4.5701
$4.75
1-Wochen-Bereich:
$4.179
$4.79
52-Wochen-Spanne:
$3.55
$100.80
Hcw Biologics Inc Stock (HCWB) Company Profile
Firmenname
Hcw Biologics Inc
Sektor
Branche
Telefon
954-842-2024
Adresse
2929 N COMMERCE PKWY, MIRAMAR
Vergleichen Sie HCWB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HCWB
Hcw Biologics Inc
|
4.71 | 11.22M | 3.50M | -37.33M | -19.15M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Hcw Biologics Inc Aktie (HCWB) Neueste Nachrichten
Why HCW Biologics Inc. stock attracts strong analyst attentionFree Stock Market Insider Analysis - Newser
What makes HCW Biologics Inc. stock price move sharplyFree Join Group - Newser
How HCW Biologics Inc. stock performs during market volatilityTrend Following Trades - Newser
HCW Biologics (NASDAQ:HCWB) Stock Price Down 0.7% – What’s Next? - Defense World
Insiders Re-Evaluate Their US$3.05m Stock Purchase As HCW Biologics Falls To US$6.9m - Yahoo Finance
HCW Biologics announces full exercise of pre-funded warrants by Armistice Capital - Investing.com
HCW Biologics Completes Warrant Exercise with Armistice - TipRanks
HCW Biologics: Pioneering Multi-Specific T-Cell Engagers in the Fight Against Solid Tumors - AInvest
HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements - GlobeNewswire
HCW Biologics regains compliance with Nasdaq listing requirements - Investing.com
HCW Biologics Board Member Resignation and Director Elections - TipRanks
HCW Biologics (NASDAQ:HCWB) Rating Lowered to “Sell” at Wall Street Zen - Defense World
HCW Biologics Sees Strong Investor Interest in June - TipRanks
HCW Biologics Inc. (NASDAQ:HCWB) Short Interest Down 85.9% in May - Defense World
HCW Biologics (NASDAQ:HCWB) Trading Down 7.6% – Here’s What Happened - Defense World
Wall Street Zen Upgrades HCW Biologics (NASDAQ:HCWB) to “Hold” - Defense World
HCW Biologics Meets Nasdaq Listing Requirements in May 2025 - TipRanks
HCW Biologics partners with WY Biotech for immunotherapy By Investing.com - Investing.com South Africa
HCW Biologics Secures Licensing Agreement with WY Biotech - TipRanks
HCW Biologics partners with WY Biotech for immunotherapy - Investing.com Australia
HCW Biologics (HCWB) Secures $7M Upfront License Fee in New Agreement with WY Biotech | HCWB Stock News - GuruFocus
HCW Biologics Completes Deliverable and Solidifies License Agreement with WY Biotech - GlobeNewswire
HCW Biologics Engages Armistice in Securities Purchase - TipRanks
HCW Biologics (NASDAQ:HCWB) Price Target Lowered to $35.00 at Maxim Group - Defense World
HCW Biologics (HCWB) Price Target Adjusted by Maxim | HCWB Stock News - GuruFocus
HCWB: Maxim Group Maintains Buy Rating, Lowers Price Target | HC - GuruFocus
HCWB: Maxim Group Maintains Buy Rating, Lowers Price Target | HCWB Stock News - GuruFocus
HCW Biologics Issues Shares Through Warrant Exercise - TipRanks
Insider Buying: Hing Wong Acquires Additional Shares of HCW Biol - GuruFocus
HCW Biologics Enters Securities Purchase Agreement - TipRanks
HCW Biologics (NASDAQ:HCWB) Trading 9.1% Higher – Still a Buy? - Defense World
HCW Biologics Inc Reports Q1 2025 Earnings: Revenue at $5,065, Net Loss Reduced to $2.2 Million - GuruFocus
HCW Biologics Reports First Quarter 2025 Business Highlights and Financial Results - The Manila Times
HCW Biologics Inc. Reports Q1 2025 Financial Results and $5 Million Equity Offering Completion - Nasdaq
HCW Biologics Closes $5 Million Public Offering - TipRanks
HCW Biologics (HCWB) Launches $5M Follow-On Offering - GuruFocus
HCW Biologics Announces Pricing of $5.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules - The Manila Times
HCW Biologics Raises Fresh Capital: $5M Follow-On Offering Includes Attractive Warrant Package - Stock Titan
HCWB Announces Maxim Group LLC as Sole Placement Agent for Offer - GuruFocus
HCWB Announces Maxim Group LLC as Sole Placement Agent for Offering | HCWB Stock News - GuruFocus
Three layers of uncertainty - The Globe and Mail
Nasdaq Rises Over 1%; Under Armour Posts Strong Q4 Sales - Benzinga
Trading Halt for HCW Biologics (HCWB) Due to Volatility | HCWB S - GuruFocus
Trading Resumes for HCW Biologics (HCWB) | HCWB Stock News - GuruFocus
HCW Biologics Reports Positive Results For HCW9206 And Opens Commercial Partnership Talks - Nasdaq
HCW Biologics Says Studies Show HCW9206 Fusion Protein Addresses Key Challenges for CAR-T Therapies; Shares Surge - marketscreener.com
HCW Biologics (HCWB) Unveils Innovative Pathway for Enhanced CAR - GuruFocus
Finanzdaten der Hcw Biologics Inc-Aktie (HCWB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):